Decimate-C Anticancer Foundation - Due diligence report

A 360° intelligence report on Decimate-C Anticancer Foundation: trust score, financial health, credit view, compliance, directors, growth an…

2012-12-27 Pune, Maharashtra Active Unlisted Active Compliant
Share
DA Decimate-C Anticancer Foundation
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Decimate-C Anticancer Foundation — 360° Intelligence Report

Generated from MCA filings & public records
77/100
Trust Score
Low Risk

Decimate-C Anticancer Foundation is assessed as Low Risk with a Trust Score of 77/100. Decimate-C Anticancer Foundation is an active private not for profit company incorporated in 2012, operating in the Healthcare sector. Reported revenue has declined across its recent filed years. It reported a loss in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and high financial risk profile.

Report generated on 21 Jul 2026 from the latest processed filings. Decimate-C Anticancer Foundation snapshot & full profile →

Financial Health › Weak
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
77/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreCaution Indicated
40/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
50/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreCaution Indicated
40/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
60/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 50/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 100/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
RHUCHA RAHUL DASARE 01234567 Director 01/04/2018 6 yrs Approved
PRERANA PRASAD PATIL 01234567 Director 01/04/2018 6 yrs Approved
ARUNDHATI ANIL RANADE 01234567 Director 01/04/2018 6 yrs Approved
  • 3 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2020 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 40 · Distress 60
Growth signals & trust indicators
Operating for 13+ years.
Distress signals & risk flags
Revenue declined year-on-year.
Losses deepening year-on-year.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment60/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view49/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • No clear growth signals in the filed years.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 13 events
21 Nov 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
30 Nov 2020
Director ceased
RHUCHA RAHUL DASARE
Director ceased
PRERANA PRASAD PATIL
30 Dec 2019
Director ceased
GIRISH KESHAV PHADKE
Director ceased
AMIT SURENDRA PARASNIS
18 Dec 2019
Director appointed
RHUCHA RAHUL DASARE (Director)
Director appointed
PRERANA PRASAD PATIL (Director)
30 Sep 2017
Director ceased
ARUNDHATI ANIL RANADE
17 Jan 2017
Director appointed
ARUNDHATI ANIL RANADE (Director)
14 Dec 2016
Director ceased
ANIL GANESH RANADE
16 Nov 2013
Director ceased
ANANTBHUSHAN ANIL RANADE
27 Dec 2012
Incorporated
Registered with Roc Pune
10

Key Observations

Auto-generated from the data above
Revenue declined 38% over the last 4 financial year(s).
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
3 active director(s) / partner(s); board looks stable and experienced.
Promoters hold a dominant controlling stake as per the FY 2020 annual return.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Zivia Ivf U85110MH2021PTC363758 Mumbai, Maharashtra, India
Good Change Health Private Limited U74999UP2020PTC129466 Ghaziabad, Uttar Pradesh, India
Elan Green Foundation U85300HR2021NPL095185 Gurgaon, Haryana, India
Sukhmani Health Care Private Limited U85199PB2005PTC027843 Sangrur, Punjab, India
Aarogita U74999HR2018PTC077062 Gurugram, Haryana, India
Doconair Private Limited U74999PB2020PTC051752 Mohali, Punjab, India
Rpm Aarogya Hospital Private Limited U85100MH2010PTC200180 Mumbai, Maharashtra, India
Atodaria Hair Transplant & Cosmetic Surgery Center Private Limited U85100GJ2013PTC075729 Surat, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Decimate-C Anticancer Foundation before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Decimate-C Anticancer Foundation: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 50/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 40/100, margin trends, ownership structure and peer set for Decimate-C Anticancer Foundation - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 77/100, distress signals and MSME payment-delay disclosures - know whether Decimate-C Anticancer Foundation pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Decimate-C Anticancer Foundation - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Decimate-C Anticancer Foundation an active company?

Decimate-C Anticancer Foundation has MCA status “Active” with a compliance score of 100/100 (Low Risk).

Is Decimate-C Anticancer Foundation financially healthy?

Decimate-C Anticancer Foundation has a Financial Health Score of 40/100 (Caution Indicated) based on its filed financial statements.

Should I do business with Decimate-C Anticancer Foundation?

Its overall Trust Score is 77/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Decimate-C Anticancer Foundation?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 3 active director(s) are on record.

Does Decimate-C Anticancer Foundation have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Decimate-C Anticancer Foundation up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).

Is it risky to lend to Decimate-C Anticancer Foundation?

Its Credit Risk Score is 50/100 (Moderate). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.